Sweden's Orexo Q4 net earnings rise on Zubsolv sale

Orexo AB

05/02/2026 06:15

Overview

Sweden-based pharmaceutical firm reported Q4 net revenues of SEK 3.3 mln for continued operations

Company sold Zubsolv US rights to Dexcel for USD 91 mln plus inventory value

Company's Q4 net earnings improved to SEK 724.8 mln, driven by discontinued operations

Outlook

Orexo expects contingent consideration up to USD 16.8 mln based on 2026-2027 sales

Company plans continued investment in AmorphOX technology and pipeline programs

Result Drivers

ZUBSOLV SALE - Sale of Zubsolv US rights to Dexcel for USD 91 mln strengthened Orexo's financial position

REVENUE DECLINE - Continued operations saw a decline in net revenues to SEK 3.3 mln

STRATEGIC FOCUS - Proceeds from Zubsolv sale to fund investment in AmorphOX technology and pipeline programs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
SEK 3.30 mln
SEK 133.62 mln (1 Analyst)
Q4 Adjusted EPS
-SEK 3.33
Q4 EPS
-SEK 3.33
Q4 EBIT
-SEK 103.20 mln
Q4 EBITDA
-SEK 70 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Orexo AB is SEK40.50, about 38% above its February 4 closing price of SEK29.35

Press Release: ID:nMFNbzdRQp

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)